Dr. Kipps makes complex science accessible as he reviews the new understanding of CLL and how they translate into new therapies and repurposing of old therapies. See bkoffman,blogspot.com for the third part of the ASH 2012 interview.
ASH 2012: Dr Kipps Interview Part 3 on genetic... - CLL Support
ASH 2012: Dr Kipps Interview Part 3 on genetics, epigenetics, and new and old CLL therapies
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
ASH 2012 Interview: Dr Jeff Sharman \"Why New CLL Treatments Supersede FCR\"
-perspective-why-new-cll-treatments-supersede-fcr
Some quotes from the interview:
\\"We're in...
ASH 2018: Dr. Kipps on antibodies and Venetoclax resistance
the first part of my interview with Dr. Kipps at ASH 2018, he discusses resistance and how to...
ASH 2013: Dr. John Pagel Discusses Radio-Immune Therapy (RIT) in Chronic Lymphocytic Leukemia (CLL)
radioimmune therapy in CLL.
It is worth listening to just to hear his clever analogy of how the...
ASH 2016: Dr. Seymour on Combination therapies with venetoclax
believer in combination therapies for CLL.
This week I'm posting an interview on our nonprofit’s...
Dr Michael Keating's Story - Taking CLL Therapies From Bedside to Community
the forefront of CLL research at M D Anderson in Texas and the creation of the CLL Global Research...